# Day with the ID Pharmacist Pager

## Antibiotic Awareness Week 2025

Jill Argotsinger, PharmD, BCIDP (MW);
Nick Kane, PharmD, BCIDP (CLT); Ethan Rausch, PharmD, BCIDP (CLT)
11.19.2025

# Disclosures

The planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.

# Learning Objectives

At the end of this session, learners should be able to:

1. Identify the roles and responsibilities of the infectious diseases and clinical pharmacist within the acute care pharmacy practice model and their impact on antimicrobial use

2. Recognize common infectious diseases questions that arise throughout clinical practice

3. Recommend an appropriate antimicrobial duration for commonly encountered infectious syndromes

**ADVOCATE**HEALTH

# Abbreviation Key

- AAW: Antibiotic Awareness Week
- AE: Adverse Event
- AMR: antimicrobial resistance
- CAP: community acquired pneumonia
- CDC: Centers for Disease Control and Prevention
- CF: cystic fibrosis
- CRE: carbapenem-resistant Enterobacterales
- DTR: difficult-to-treat resistance
- ESBL: extended-spectrum β-lactamase
- HAP: hospital acquired pneumonia
- IDSA: Infectious Diseases Society of America

- KPC: *Klebsiella pneumoniae* carbapenemase
- MBL: Metallo-β-lactamase
- MDR: multidrug resistant
- NHSN: National Healthcare Safety Network
- OXA-48: oxacillinase-48
- MSSA: Methicillin Susceptible *Staphylococcus aureus*
- MRSA: Methicillin Resistant *Staphylococcus aureus*
- PTC: Pneumonia Short Treatment trial
- VAP: Ventilator associated pneumonia

ADVOCATE HEALTH

# Antibiotic Awareness Week 2025

Global initiative highlighting the importance of antimicrobial resistance, its impact, and appropriate antimicrobial use

Why does it matter?

| | | |
|---|---|---|
| AMR responsible for 2.8 million infections and >35k deaths annually | **> 50%** of inpatients receive antimicrobials<br><br>At least **30%** require optimization | 1 in 5 patients may experience an AE while on antibiotic therapy in the hospital |

CDC. Antibiotic Resistance Threats in the United States, 2019.
Fridkin S et al. MMWR Morb Mortal Wkly Rep. 2014;63:194-200.
Tamma P et al. JAMA Intern Med. 2017;177:1308-1315.

ADVOCATE HEALTH

# Antibiotic Awareness Week 2025



Everyone likely has at least one daily opportunity to optimize antimicrobial use:

- Right patient
- Right dose
- Right duration
- Right drug
- Right route

CDC. US AAW Toolkit. 2025

# Empiric Antibiotics – When to Go Broad?

# When you hear "broad-spectrum antibiotics," which antibiotics come to mind?

- There's no clear consensus and several different scoring systems to assess "broadness"
- NHSN, a CDC program, provides antimicrobial groupings to distinguish "narrow" from "broad" spectrum antimicrobials

ADVOCATEHEALTH

# NHSN Antimicrobial Groupers
## *Adults*

- NHSN antimicrobial groupings are used to contextualize and report antimicrobial utilization data

- Examples of antimicrobial grouping designations:
  - **Narrow-Spectrum Beta-Lactams**: amoxicillin/clavulanate, ampicillin/sulbactam, cefazolin, penicillin
  - **Broad-Spectrum Community-Acquired**: ceftriaxone, fluoroquinolones, ertapenem
  - **Broad-Spectrum Hospital-Onset**: aztreonam, cefepime, ceftazidime, meropenem, piperacillin/tazobactam
  - **Extensively Broad-Spectrum**: ceftazidime/avibactam, ceftolozane/tazobactam, tigecycline, cefiderocol, meropenem/vaborbactam

CDC. NHSN Guide to the SAAR. 2025.

ADVOCATE HEALTH

# When you hear "broad-spectrum antibiotics," which antibiotics come to mind?

- For today's presentation, we'll largely focus on antipseudomonal agents and agents that cover MDR pathogens

# Assessment Question #1

**A 35-year-old female patient was admitted from the community with septic shock in the setting of multifocal pneumonia. She has a history of basal cell carcinoma (stage 1 s/p excision) and no recent antibiotic exposure. The patient's provider contacts pharmacy for empiric antimicrobial recommendations.**

Which antimicrobial regimen and rationale is most appropriate?

A. Ceftazidime/avibactam + vancomycin + azithromycin; to ensure any possible pathogen is covered given presence of septic shock

B. Ceftriaxone + azithromycin; standard CAP therapy should suffice

C. Cefepime + vancomycin; HAP-directed therapy should be utilized given history of immunocompromising condition

D. Antimicrobials are not necessary; this is likely viral pneumonia

# Empiric Antimicrobial Selection in Sepsis & Septic Shock

- Before deciding on an empiric regimen for a patient presenting with sepsis/septic shock, the following must be considered:
  - What the likely source of infection is
  - What the likely pathogens are
    - Based on likely source, local resistance, and patient-specific history/microbiological history
  - How catastrophic the outcome would be if there was a delay in effective antimicrobials
    - Of note, the presence of septic shock in and of itself is NOT a risk factor for multidrug resistant infection and does NOT increase risk of inappropriate empiric treatment

Kollef MH. 2019. PMID:30535353.
Strich JR. 2020. PMID:32691833.

ADVOCATE HEALTH

# Empiric Antimicrobial Selection in Sepsis & Septic Shock



Kollef MH. 2019. PMID:30535353.

# Empiric Antimicrobial Selection in Sepsis & Septic Shock



Kollef MH. 2019. PMID:30535353.

# Assessment Question #1

A 35-year-old female patient was admitted from the community with septic shock in the setting of multifocal pneumonia. She has a history of basal cell carcinoma (stage 1 s/p excision) and no recent antibiotic exposure. The patient's provider contacts pharmacy for empiric antimicrobial recommendations.

Which antimicrobial regimen and rationale is most appropriate?

A. Ceftazidime/avibactam + vancomycin + azithromycin; to ensure any possible pathogen is covered given presence of septic shock

B. Ceftriaxone + azithromycin; standard CAP therapy should suffice

C. Cefepime + vancomycin; HAP-directed therapy should be utilized given history of immunocompromising condition

D. Antimicrobials are not necessary; this is likely viral pneumonia

**A 65-year-old female patient was admitted with septic shock in setting of multifocal pneumonia. She has a history of bronchiectasis and colonization with MDR *P. aeruginosa*.**

Does this patient warrant "broad-spectrum" (e.g. antipseudomonal or MDR-active) empiric therapy?

YES – select agent based on prior susceptibility data; if no agent covers all prior pathogens, consider combination therapy

# Empiric Antimicrobial Selection in Non-Septic Patients

- FOMO (Fear of Missing Organisms) often results in the use of overly broad-spectrum antimicrobials

- In non-septic patients, the risks associated with use of broad-spectrum antimicrobials often outweighs potential benefit

- Common infectious disease states that often include unnecessarily broad-spectrum treatment:
  - Diabetic foot infection: *P. aeruginosa* is not as common as once thought, new guidelines do not recommend empiric antipseudomonal coverage in most cases
  - CAP: empiric antipseudomonal therapy is typically not required, but still often utilized

Baghdadi JD. 2025. PMID:39874272.
Morelli MK. 2023. PMID:38028912.

ADVOCATE HEALTH

# Empiric Antimicrobial Selection if Prior MDR Pathogen

- For patients with a history of MDR organisms (CRE, DTR Pseudomonas, etc.) that may require empiric coverage of those organisms:
  - Consider consultation of an ID physician and pharmacist
  - Evaluate prior susceptibility information and carbapenemase gene detection, if applicable
  - Evaluate which antimicrobial agent the patient received for that organism previously
  - Review institutional guidance document(s)
    - These documents largely align with the IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections

ADVOCATE HEALTH

# Empiric Antimicrobial Selection if Prior MDR Pathogen

- Newer β-lactam/β-lactamase inhibitor combinations are often preferred empiric and targeted options for MDR pathogens

| | KPC | MBL | OXA-48 | DTR Pseudomonas |
|---|---|---|---|---|
| Cefiderocol | Yellow | Green | Yellow | Yellow |
| Ceftazidime/avibactam | Yellow | Gray | Green | Yellow |
| Ceftolozane/tazobactam | Gray | Gray | Gray | Green |
| Imipenem/relebactam | Yellow | Gray | Gray | Green |
| Meropenem/vaborbactam | Green | Gray | Gray | Gray |
| Aztreonam/avibactam | Yellow | Green | Yellow | Yellow |

Green = 1st line; Yellow = 2nd line/alternative; Gray = no coverage

Tamma PD. 2024. PMID:39108079.
Hsu AJ. 2025. PMID:39976357.

ADVOCATE HEALTH

# Common Empiric Antimicrobial Pitfalls

- Broadening coverage after < 24 hours of an antimicrobial agent
    - May not be enough time to see an adequate response to therapy

- Initiating antipseudomonal antibiotics for all patients with any immunocompromising condition
    - Assess degree of immunosuppression, risk factors for resistance, healthcare exposure, etc.

- Initiating a carbapenem for any patient with prior ESBL isolation
    - If ESBL was isolated a long time ago (especially if repeat cultures from the same site have not grown ESBL), can likely forego ESBL coverage
    - If ESBL was isolated from a site that is different from the current infectious site, may be able to forego ESBL coverage

- Failure to adjust empiric therapy once additional data becomes available
    - Once susceptibilities are confirmed or infection is ruled out, antimicrobials should be targeted

ADVOCATE HEALTH

# Empiric Antimicrobial Selection Take-Home Points

- Empiric antimicrobial selection is based on several factors

- Individually assess patients to determine antimicrobial spectrum appropriateness

- Optimizing antimicrobials from the get-go is the best way to impact therapy
  - Once antimicrobial agents are started, it's harder to de-escalate

- At Advocate, we have several resources available to support pharmacists when assessing empiric antimicrobial regimens
  - Institution-specific empiric antimicrobial guidelines
  - ID pharmacists are available for secondary review/questions

Strich JR. 2020. PMID:32691833.

ADVOCATE HEALTH

# Shorter is "Better"

Duration=powerful tool to curb antimicrobial resistance

- Prolonged antimicrobial exposure/overall antimicrobial exposure consistently linked to increased AMR

- Underexposure may also increase risk

Shift from standard "Constantine" units to patient-oriented duration

Randomized control data to support shorter durations for:

- Bacteremia

- Pyelonephritis

- Skin and soft tissue infection

- **CAP? HAP/VAP?**



ANTIMICROBIAL DURATIONS OF THERAPY
Too Much | Just Right | Too Little

Created with Microsoft Copilot. 10.16.25

ADVOCATE HEALTH

Spellberg B et al. Ann Intern Med. 2019;171:210-211.

# The Case for CAP: PTC

| Pneumonia Short Treatment (PTC): 3 vs 5 Days of Therapy | |
|---|---|
| Design | Double Blind, placebo-controlled, multi-center, non inferiority randomized control trial<br>Non-ICU, Adults with moderately severe CAP<br>Meet stability criteria* at day 3 |
| Intervention Comparator | 3 days: Placebo to complete 5 days<br>8 days: Amoxicillin/Clavulanate 500/62.5 mg TID x 5days |

| Baseline, n (%) | 3 days (n=152) | 8 days (n=151) |
|---|---|---|
| Age, avg yr (IQR) | 72.5 (54.0-85.3) | 74.0 (58.0-83.0) |
| Comorbidities | 34 (22) | 39 (26) |
| PSI 3 -5 | 96 (63) | 96 (64) |
| O2 therapy | 60 (39) | 59 (39) |

**ADVOCATE**HEALTH

Dinh A, et al. Lancet. 2021;397:1195-203.

# The Case for CAP: PTC Results

## 15 Day Clinical Cure



Risk Difference
9.42% (95% CI -0.38 to 20.04)

No significant difference seen in 30d cure, mortality, length of stay, time to recovery, or any subgroup of interest (age, severity)

Dinh A, et al. Lancet. 2021;397:1195-203.

# CAP Guideline Updates

IDSA 2019

- 5 days if meeting clinical stability criteria
- 7 days MRSA or Pseudomonas

ATS 2025

- **3-5 days** if meeting clinical stability criteria

IDSA 2025 ???

Clinically Stable
- Afebrile
- HR <100 BPM
- RR<24
- SBP>90 mmHg
- SpO2≥90%

- Normal mentation

Metlay et al. Am J Respir Crit Care Med. 2019;200:e45-e67.
Jones B et al. Am J Respir Crit Care Med. 2025.

ADVOCATE HEALTH

# Shorter durations for HAP/VAP

1995: Typically recommended 14-21 days

2003: PneumA 8d vs. 15d RCT shows non-inferiority

2005: Guidelines updated to reflect 7-8d duration (excluding *P. aeruginosa*)

2016: Methodologically flawed meta-analysis of available data shows no difference for *P.aeruginosa* outcomes > Guidelines updated to 7-8d for all

**Is there any room to optimize?**

# A Case for HAP/VAP?

| Reducing Antibiotics Treatment Duration for Ventilator-Associated Pneumonia (REGARD-VAP) | | |
|---|---|---|
| Design | Single blind, multi-center, hierarchical non-inferiority-superiority, randomized control trial in southeast Asia<br>Adult, ICU, VAP (CDC), **met pre-defined stability criteria** at randomization | |
| Intervention<br>Comparator | Individualized short course (at least 3-5 days)<br>Usual care determined by physician | |
| **Baseline, n (%)** | **Short Course (n=231)** | **Usual Care (n=229)** |
| Age, median yr(IQR) | 63 (50-73) | 64.0 (52-75) |
| SOFA, median(IQR) | 6 (4-8) | 6 (4-8) |
| Time to therapy, d | 0 (0-3) | 0 (0-2) |
| Surgical ICU | 160 (69) | 156 (68) |
| Carbapenem-R | 76 (33) | 65 (28) |
| Fever | 176 (76) | 189 (83) |
| Inotropes | 40 (17) | 47 (21) |

Ma Y et al. Lancet Respir Med. 2024;12:399-408.

# A Case for HAP/VAP?

| Primary Outcome, n(%) | Short Course (n=231) | Usual Care (n=229) |
|---|---|---|
| All Cause Mortality or Recurrence at 60 days | 95 (41) | 100 (44) |
| | Adjusted Absolute Risk -2% (95% CI -∞ to 5%) | |
| All cause mortality | 81 (35) | 33 (14%) |
| Recurrence | 33 (14) | 30 (13) |

Duration of Antimicrobials

- Short Course: 6d (IQR 5-7)

- Usual care: 14d (IQR 10-21)

Fewer overall side effects short course group (AKI), no difference Hospital/ventilator duration

ADVOCATE HEALTH

Ma Y et al. Lancet Respir Med. 2024;12:399-408.

# Conclusions

Patient specific durations may be more appropriate for pneumonia duration

If clinically improved

- Consider 3 days in non-sever CAP
- Consider 5-7 days for HAP/VAP

Each day does matter! May not need to stick to "standard" duration buckets – 7 vs 5 vs 4 vs 6

ADVOCATE HEALTH

# Assessment Question #2

AI is a 55 year old male with uncontrolled type 2 diabetes and COPD he presents with productive cough, fever, and shortness of breath on exertion over the past 3 days. Chest Xray reveals dense lobar infiltrate in left lower lobe. AL is started on ceftriaxone and admitted to the hospital.

It is day 3 of ceftriaxone and AL will be discharged

Which recommendation best reflects the clinical pharmacist's responsibility in optimizing antimicrobial use for this patient upon discharge?

A. Amoxicillin/Clavulanate  875mg/125mg PO BID x 2 days

B. Ciprofloxacin 500mg BID x 5 days

C. Keep inpatient to complete 5 days of IV therapy

D. Amoxicillin/Clavulanate 875mg/125mg PO BID x5 days

E. No further antibiotics at discharge

Temp: 98°F

BP: 150/95 mmHg

HR: 75 BPM

RR: 20

Oxygen Saturation: 95% on room air

ADVOCATE HEALTH

# Culture Interpretation – Common Contaminants

# Help!

- You are staffing and get notified of a positive blood culture for patient MB:



- Gram positive bacilli present in 1 out of 2 cultures, Biofire did not identify an organism
- Patient is currently not on any antibiotics and is clinically stable

# Contaminant?

- Contaminant = presence of an organism in a culture that is typically acquired during acquisition or processing of the specimen that is not causing an infection

- Blood cultures may be contaminated by a limited range of Gram-positive commensal organisms
  - Ex. coagulase-negative staphylococci, *Corynebacterium* spp., *Bacillus* spp.
    - *S. epidermidis, S. saprophyticus, S. hominis, S. haemolyticus, S. capitis, S. warneri, S. simulans*

- Determination of the likelihood of contamination versus true bacteremia is based on clinical judgement when a blood culture grows a gram-positive skin commensal

  **When a commensal skin organism causes an actual infection, it is often related to an indwelling catheter or device**

# Contaminant?

| Factor | Contaminant | True Bacteremia |
|---|---|---|
| Number of positive sets of blood cultures | Usually only one* | two or more cultures |
| Time to positive culture | Often slower (>2 days) | Usually rapid |
| Central venous catheter, prosthetic heart valve or other clinical risk | Often absent | Usually present |
| Patient-related risk for contaminants (ex. difficult stick) | Can be present | Often absent |

*One positive blood culture for a possible contaminant with an alternate explanation for the symptoms that prompted the culture is almost always a contaminant. However, if patients have prosthetic material, careful assessment is advised as they may be pathogenic.

# Contaminant?

- **Gram-negatives, yeast, *S. aureus* (MSSA or MRSA) *S. lugdunensis*, most *Streptococcus spp*. and most anaerobes** are almost <u>**NEVER**</u> contaminants

- A diagnosis of contamination should not be invoked to justify withholding antimicrobial therapy for patients with a blood culture growing one of these organisms unless under the guidance of Infectious Diseases consultation

# Remember MB?

- Gram positive bacilli present in 1 out of 2 cultures

**Follow a step-wise approach:**

1. Are there two cultures showing growth of the same organism?

2. Is the organism identified as a gram-negative bacilli or yeast?

3. Is the organism a gram-positive cocci in pairs or chains? i.e., *Streptococcus spp.?*

4. Is the organism gram positive cocci in clusters, identified as *Staphylococcus aureus*?

# Remember MB?

- Consider patient risk factors associated with poor outcome

    - Risk factors include:
        - Immunocompromised
        - Internal hardware (artificial heart valve, pacemaker, prosthetic joints),
        - Suspicion/history of endocarditis
        - Central line
        - Concern for osteomyelitis/discitis

- Consider which is showing growth
    - Anaerobic vs aerobic

ADVOCATE HEALTH

# Remember MB?

What if…

- The chart describes a 70-year-old male who presented with alerted mental status concerning for meningitis. Blood cultures were drawn as sepsis was on the differential and he is pending a lumbar puncture. Empirically started on vancomycin, ceftriaxone, and acyclovir.

VS

- The chart describes a healthy 20-year-old non-pregnant female presenting for respiratory symptoms who has no concerning past medical history.

# Stratify the Bacteria by Risk

Find the bacteria below and determine if it is HIGH, INTERMEDIATE, or LOW risk.

| Species | Gram Stain | Morphology | Subclassification | Approx % chance of true bacteremia if single bottle positive | Risk Group |
|---|---|---|---|---|---|
| Bacillus anthracis | Gram pos | bacilli | | >80 | High |
| Clostridium botulinum | Gram pos | bacilli | anaerobe | >80 | High |
| Clostridium difficile | Gram pos | bacilli | anaerobe | >80 | High |
| Clostridium spp. (except C. botulinum, C. difficile, C. tetani) | Gram pos | bacilli | anaerobe | 64 | High |
| Clostridium tetani | Gram pos | bacilli | anaerobe | >80 | High |
| Corynebacterium jeikeinum | Gram pos | bacilli | | >80 | High |
| Listeria monocytogenes | Gram pos | bacilli | | >80 | High |
| Mycobacterium spp. | Gram pos | bacilli | Mycobacteria | 100 | High |
| Nocardia spp. | Gram pos | bacilli | | >80 | High |
| Clostiridium perfringens | Gram pos | bacilli | anaerobe | 25 | Intermediate |
| Lactobacillus spp. | Gram pos | bacilli | anaerobe | 50 | Intermediate |
| Bacillus spp. (except B. anthracis) | Gram pos | bacilli | | <5 | Low |
| Corynebacterium spp.(except C. jeikeium) | Gram pos | bacilli | | <5 | Low |
| Paenibacillus spp. | Gram pos | bacilli | | <5 | Low |
| Propionibacterium spp. | Gram pos | bacilli | anaerobe | 3 | Low |
| Rhodococcus spp. | Gram pos | bacilli | | <5 | Low |

Hall KK. 2006. *Clin. Microbiol. Rev.*

ADVOCATE HEALTH

# Culture Interpretation – Bug Drug Mismatch

# Help!

- You are staffing and are reviewing the following culture for NS:

Susceptibility

| | Escherichia coli MIC (Preliminary) | |
|---|---|---|
| Amikacin | 2 ug/mL | Susceptible |
| Ampicillin | >=32 ug/mL | Resistant |
| Ampicillin/Sulbactam | 16 ug/mL | Intermediate |
| Cefazolin | >=32 ug/mL | Resistant [1] |
| Cefazolin (Urine) | >=32 ug/mL | Resistant [2] |
| Cefepime | 8 ug/mL | Susceptible dose dependent |
| Ceftriaxone | >=64 ug/mL | Resistant |
| Ciprofloxacin | >=4 ug/mL | Resistant |
| Ertapenem | <=0.12 ug/mL | Susceptible |
| ESBL | Positive ug/mL | Positive [3] |
| Gentamicin | >=16 ug/mL | Resistant |
| Meropenem | <=0.25 ug/mL | Susceptible |
| Nitrofurantoin | <=16 ug/mL | Susceptible |
| Piperacillin/Tazobactam | <=4 ug/mL | Susceptible |
| Trimethoprim/Sulfamethoxazole | >=320 ug/mL | Resistant |

- NS is admitted for community acquired pneumonia and is currently on ceftriaxone 2 g IV daily

# Urine Cultures

- Pyuria **PLUS** symptoms = UTI

  Asymptomatic treatment only in pregnancy and prior to urological procedures

- Altered mental status alone is not indicative of a UTI



**Old Classifications**

**Uncomplicated UTI:** Acute cystitis in afebrile nonpregnant premenopausal women with no diabetes and no urologic abnormalities

**Acute Pyelonephritis:** Acute kidney infection in women otherwise meeting the definition of uncomplicated UTI above

**Complicated UTI:** All other UTIs

**New Classifications**

**Uncomplicated UTI: Infection confined to the bladder** in afebrile women or men

**Complicated UTI: infection beyond the bladder** in women or men
- Pyelonephritis
- Febrile or bacteremic UTI
- Catheter-associated (CAUTI)
- Prostatitis* (*not covered by these guidelines)

Trautner et al., Infectious Diseases Society of America, 2025

**ADVOCATE**HEALTH

# Sputum Culture

- Colonization is common
  - Need clinical correlations for determination of treatment

- Some organisms virtually never considered pulmonary pathogens:
  - Coagulase negative *Staphylococcus*
  - *Enterococci*
  - Gram positive bacilli (except *Nocardia*)

- MRSA Nasal PCR – high negative predictive value
  - If negative: MRSA is NOT the cause of your pneumonia

- Aspiration pneumonia – no anaerobic coverage warranted

Shi et al., The Journal of Infectious Diseases, 2020
Mohanty et al., The Journal of Infectious Diseases, 2024

ADVOCATE HEALTH

# Remember NS?

ESBL producing *E. coli* in urine culture

**Follow a step-wise approach:**

1. Is treatment indicated?
2. Is current treatment effective?
3. Can coverage be narrowed?
4. Can I adjust to PO if improved? Does the dose need adjusted?
5. Can I define duration?

# Remember NS?

What if…

- The chart describes a 70-year-old male who presented with alerted mental status, shortness of breath with chest x-ray findings consistent with pneumonia. Urine culture was drawn in the ED because of the altered mental status but his other urinary symptoms are unremarkable

VS

- A pregnant 24-year-old female with this positive culture who came in complaining of uncontrolled nausea and vomiting

# Assessment Question #3

RK is a 76-year-old male with a past medical history of small bowel obstruction, chronically on TPN via a central line presenting with fevers, and chills. He has empirically been started on cefepime. His blood culture is 1 of 2 positive for a gram-positive cocci in clusters, identified as a *Staphylococcus spp.* Which recommendation best reflects the clinical pharmacist's responsibility in optimizing antimicrobial use for bacteremias?

A. This is a contaminant given in 1 of 2, no additional therapy needed.

B. This is NOT a contaminant given presence of a central line, recommend the addition of vancomycin

C. This is unable to be interpreted given only 1 culture positive. Hold adding antibiotics and repeat blood cultures.

D. This is a contaminant, but we should add vancomycin anyways because there's no harm in adding a

🚑 **BLOOD CULTURE, RAPID IDENTIFICATION**

Status: **Final result**   Visible to patient: **Yes (not seen)**

Specimen Information:  **Blood, Venous**

**0**  Result Notes

| Component | Ref Range & Units | 5 d ago |
|---|---|---|
| Staphylococcus species | Not Detected | **Detected ‼️** |
| Staphylococcus aureus | Not Detected | Not Detected |
| Staphylococcus lugdunensis | Not Detected | Not Detected |
| Enterococcus faecalis | Not Detected | Not Detected |
| Enterococcus faecium | Not Detected | Not Detected |
| Streptococcus species | Not Detected | Not Detected |
| Streptococcus agalactiae | Not Detected | Not Detected |
| Streptococcus pneumoniae | Not Detected | Not Detected |
| Streptococcus pyogenes | Not Detected | Not Detected |
| Listeria monocytogenes | Not Detected | Not Detected |
| Enterobacterales | Not Detected | Not Detected |
| Enterobacter cloacae complex | Not Detected | Not Detected |
| Escherichia coli | Not Detected | Not Detected |
| Klebsiella aerogenes | Not Detected | Not Detected |
| Klebsiella oxytoca | Not Detected | Not Detected |
| Klebsiella pneumoniae | Not Detected | Not Detected |
| Proteus species | Not Detected | Not Detected |
| Salmonella species | Not Detected | Not Detected |
| Serratia marcescens | Not Detected | Not Detected |
| Acinetobacter baumannii | Not Detected | Not Detected |
| Pseudomonas aeruginosa | Not Detected | Not Detected |
| Stenotrophomonas maltophilia | Not Detected | Not Detected |
| Bacteroides fragilis | Not Detected | Not Detected |
| Haemophilus influenzae | Not Detected | Not Detected |
| Neisseria meningitidis | Not Detected | Not Detected |
| Candida albicans | Not Detected | Not Detected |
| Candida auris | Not Detected | Not Detected |
| Candida glabrata | Not Detected | Not Detected |
| Candida krusei | Not Detected | Not Detected |
| Candida parapsilosis | Not Detected | Not Detected |
| Candida tropicalis | Not Detected | Not Detected |
| Cryptococcus neoformans/gattii | Not Detected | Not Detected |

ADVOCATE HEALTH

# Summary

Everyone has a role in fighting antimicrobial resistance

Optimizing antibiotic use includes appropriate empiric therapy and limiting duration

Critical evaluation of cultures is necessary to determine need for therapy

Ask for help if unsure

ADVOCATE HEALTH

# References

- Centers for Disease Control and Prevention. The NHSN Standardized Antimicrobial Administration Ratio (SAAR). Revised July 28, 2025. Accessed October 9, 2025. https://www.cdc.gov/nhsn/pdfs/ps-analysis-resources/aur/au-saar-guide-508.pdf

- Kollef MH, Burnham JP. Antibiotic thresholds for sepsis and septic shock. *Clin Infect Dis*. 2019 Aug 30;69(6):938-940. doi:10.1093/cid/ciy1035.

- Strich JR, Heil EL, Masur H. Considerations for empiric antimicrobial therapy in sepsis and septic shock in an era of antimicrobial resistance. *J Infect Dis*. 2020 Jul 21;222(Suppl 2):S119-S131. doi:10.1093/infdis/jiaa221.

- Baghdadi JD, Goodman KE, Magder LS, et al. Association between delayed broad-spectrum gram-negative antibiotics and clinical outcomes: how much does getting it right with empiric antibiotics matter. *Clin Infect Dis*. 2025 Jun 4;80(5):949-958. doi:10.1093/cid/ciaf039.

- Morelli MK, Son AH, Bitar Y, Hecker MT. Fear of missing organisms (FOMO): the discordance among broad-spectrum empiric antibiotic therapy, microbiologic results, and definitive antibiotic therapy for diabetic foot infections and lower extremity osteomyelitis. *Antimicrob Steward Healthc Epidemiol*. 2023 Oct 25;3(1):e186. doi:10.1017/ash.2023.467.

- Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. *Clin Infect Dis*. 2024 Aug 7:ciae403. doi:10.1093/cid/ciae403.

- Hsu AJ, Chiotos K, Heil EL, et al. The effectiveness of newer beta-lactams for the treatment of antimicrobial-resistant gram-negative meningitis. *Clin Infect Dis*. 2025 Jun 4;80(5):959-968. doi:10.1093/cid/ciaf071.

- Trautner BW, Lavergne V, et al. Complicated urinary tract infections (cUTI): clinical guidelines for treatment and management. Infectious Diseases Society of America, 2025 Jul 17.

**ADVOCATE**HEALTH

# Questions?

Jill Argotsinger (**Jill.Argotsinger@aah.org**);
Nick Kane (**Nicholas.Kane@advocatehealth.org**);
Ethan Rausch (**Ethan.Rausch@advocatehealth.org**)